Aktienanalyse zu Annexon, Inc. (ANNX)ANNXAnnexon, Inc.

Annexon, Inc. is a biopharmaceutical company advancing targeted immunotherapies aimed at complement-mediated neuroinflammatory diseases. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Tanruprubart is an investigational-targeted immunotherapy delivered in a single infusion to rapidly halt aggressive neuroinflammation and damage in GBS, an acute, rare, neuromuscular emergency. The Vonaprument is an investigational neuroprotective inhibitor of C1q and the classical complement cascade delivered intravitreally for dry AMD with GA, a leading cause of blindness. ANX1502, a novel oral small molecule for autoimmune conditions. The Company's next wave programs include ANX005 and ANX009. ANX009, a C1q-blocking Fab formulated for subcutaneous delivery, for patients with lupus nephritis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Annexon Inc. (ANNX) appears to be a good buy right now due to its current price of $3.75 being significantly lower than the analyst price target of $15 from JPMorgan, indicating a potential upside of 300%. Additionally, the stock's recent 5-day change of +9.97% suggests positive momentum. However, the main risk is the negative earnings trend, with a projected EPS of -0.23 for Q1 2026, which could impact investor sentiment.